Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

231 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL, Disis ML. Knutson KL, et al. Cancer Immunol Immunother. 2005 Aug;54(8):721-8. doi: 10.1007/s00262-004-0653-2. Epub 2005 Jan 27. Cancer Immunol Immunother. 2005. PMID: 16010587 Review.
Immunotherapeutic approaches for the treatment of breast cancer.
Knutson KL, Schiffman K, Rinn K, Disis ML. Knutson KL, et al. J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):353-65. doi: 10.1023/a:1018714300217. J Mammary Gland Biol Neoplasia. 1999. PMID: 10705919 Review.
Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.
Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Disis ML, et al. Among authors: knutson kl. Clin Cancer Res. 2000 Apr;6(4):1347-50. Clin Cancer Res. 2000. PMID: 10778962
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
Knutson KL, Schiffman K, Disis ML. Knutson KL, et al. J Clin Invest. 2001 Feb;107(4):477-84. doi: 10.1172/JCI11752. J Clin Invest. 2001. PMID: 11181647 Free PMC article.
Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL, Disis ML. Knutson KL, et al. Clin Breast Cancer. 2001 Apr;2(1):73-9. doi: 10.3816/CBC.2001.n.014. Clin Breast Cancer. 2001. PMID: 11899386 Review.
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL, Schiffman K, Cheever MA, Disis ML. Knutson KL, et al. Clin Cancer Res. 2002 May;8(5):1014-8. Clin Cancer Res. 2002. PMID: 12006513 Clinical Trial.
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Disis ML, et al. Among authors: knutson kl. J Clin Oncol. 2002 Jun 1;20(11):2624-32. doi: 10.1200/JCO.2002.06.171. J Clin Oncol. 2002. PMID: 12039923 Clinical Trial.
Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
Knutson KL, Disis ML. Knutson KL, et al. Hum Immunol. 2002 Jul;63(7):547-57. doi: 10.1016/s0198-8859(02)00401-9. Hum Immunol. 2002. PMID: 12072190
Immunotherapy for breast cancer.
Knutson KL, Bishop MR, Schiffman K, Disis ML. Knutson KL, et al. Cancer Chemother Biol Response Modif. 2002;20:351-69. Cancer Chemother Biol Response Modif. 2002. PMID: 12703214 Review. No abstract available.
Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.
Disis ML, Shiota FM, McNeel DG, Knutson KL. Disis ML, et al. Among authors: knutson kl. Immunobiology. 2003;207(3):179-86. doi: 10.1078/0171-2985-00230. Immunobiology. 2003. PMID: 12777059
231 results
Jump to page
Feedback